Product data
- Dosage form
- Cream
- Dosage-form group
- Topical
- Therapeutic area
- Neuropathic pain
- Reference product
- Capsule 100, 200 mg; tablet 300–800 mg; oral solution 250 mg/5 mL
- Status
- POC established / under development
- Development stage
- 1 of 5 · Proof of concept
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23